Steve Davies obtained his BA in 1973 from the University of Oxford and his D.Phil. in 1975. He subsequently held an ICI Postdoctoral Fellowship (1975-1977) and a NATO Fellowship (1977-1978) before joining the CNRS at Gif-sur-Yvette as Attaché de Recherche. In 1980 he returned to Oxford to take up a University Lectureship in Chemistry. In 1996, he became Professor of Chemistry (Oxford) and in 2006, the Waynflete Professor of Chemistry (Oxford). Whilst remaining an active academic, Davies founded Oxford Asymmetry Ltd (an asymmetric synthesis company) in 1991 as sole investor.  He also founded Oxford Diversity Ltd (a combinatorial chemistry company). These two companies were merged to form Oxford Asymmetry International Plc in 1999 which was sold to Evotec in 2000 for £316m. In 2003 he founded VASTox (Value Added Screening Technology Oxford), a zebrafish screening company. It floated on AIM in 2004 and changed its name to Summit plc in 2007. Summit raised £23m in a follow-on offering in 2014 in order to conduct  phase 2 studies of a utrophin modulator, discovered in Davies’ lab, in Duchenne Muscular Dystrophy and an in-licensed small molecule for the treatment of Clostridium difficile. In addition, Davies is founder and editor-in-chief for Tetrahedron: Asymmetry. Steve Davies obtained his BA in 1973 from the University of Oxford and his D.Phil. in 1975. He subsequently held an ICI Postdoctoral Fellowship (1975-1977) and a NATO Fellowship (1977-1978) before joining the CNRS at Gif-sur-Yvette as Attaché de Recherche. In 1980 he returned to Oxford to take up a University Lectureship in Chemistry. In 1996, he became Professor of Chemistry (Oxford) and in 2006, the Waynflete Professor of Chemistry (Oxford). Whilst remaining an active academic, Davies founded Oxford Asymmetry Ltd (an asymmetric synthesis company) in 1991 as sole investor.  He also founded Oxford Diversity Ltd (a combinatorial chemistry company). These two companies were merged to form Oxford Asymmetry International Plc in 1999 which was sold to Evotec in 2000 for £316m. In 2003 he founded VASTox (Value Added Screening Technology Oxford), a zebrafish screening company. It floated on AIM in 2004 and changed its name to Summit plc in 2007. Summit raised £23m in a follow-on offering in 2014 in order to conduct  phase 2 studies of a utrophin modulator, discovered in Davies’ lab, in Duchenne Muscular Dystrophy and an in-licensed small molecule for the treatment of Clostridium difficile. In addition, Davies is founder and editor-in-chief for Tetrahedron: Asymmetry.

fermentation